Article
Immunology
Tzu-Rong Peng, Chao-Chuan Wu, Sou-Yi Chang, Yen-Chih Chen, Ta-Wei Wu, Ching-Sheng Hsu
Summary: This study investigated the therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable HCC. The findings showed that the combination therapy resulted in better overall survival outcomes compared to sorafenib alone.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Gong Zhang, Yufeng Wang, Bryan C. Fuchs, Wei Guo, David L. Drum, Derek J. Erstad, Baomin Shi, Albert B. DeLeo, Hui Zheng, Lei Cai, Liyuan Zhang, Kenneth K. Tanabe, Xinhui Wang
Summary: The combination of DSF/Cu and sorafenib can effectively treat HCC by targeting HCSCs both in vitro and in vivo. DSF/Cu enhances the sensitivity of HCC cells to sorafenib, inhibits proliferation of HCC cells, and decreases the stemness of HCC cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Wenying Qiao, Qi Wang, Caixia Hu, Yinghua Zhang, Jianjun Li, Yu Sun, Chunwang Yuan, Wen Wang, Biyu Liu, Yonghong Zhang
Summary: The addition of anti-PD-1 adjuvant therapy after TACE combined with ablation was found to significantly prolong relapse-free survival in early-to-mid-stage HCC patients with high recurrence risk, with manageable safety.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Engineering, Biomedical
Jun Hu, Jing Hu, Wenrui Wu, Yufei Qin, Junjie Fu, Chao Liu, Peter H. Seeberger, Jian Yin
Summary: This study presents the development of a nanoplatform, Sor@GR-COF-366, for synergistic chemotherapy and photodynamic therapy (PDT) in hepatocellular carcinoma (HCC). The nanoplatform combines a porphyrin-based covalent organic framework (COF-366) with N-acetyl-galactosamine (GalNAc), rhodamine B (RhB), and Sorafenib (Sor). It shows targeted delivery to ASGPR-overexpressed HCC cells and liver tissues, exerting enhanced tumor suppression effects and prolonging survival in mouse models with low toxicity. The combination of biomedical nano-formulation with clinical operational means holds great promise for clinical translation in cancer treatment.
ACTA BIOMATERIALIA
(2022)
Article
Medicine, Research & Experimental
Jialiang Luo, Lei Li, Zhengyumeng Zhu, Bo Chang, Fan Deng, Di Wang, Xiao Lu, Daming Zuo, Qingyun Chen, Jia Zhou
Summary: This study demonstrated that the combination of fucoidan and sorafenib could overcome sorafenib resistance in hepatocellular carcinoma cells by interacting with cell membrane EGFR and suppressing EGFR redistribution and downstream signaling. The simultaneous treatment of fucoidan and sorafenib might serve as a potential therapeutic strategy against sorafenib-resistant HCC.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Qinqin Liu, Nan You, Jing Li, Ke Wu, Xuehui Peng, Zheng Wang, Liang Wang, Yinan Zhu, Lu Zheng
Summary: The study found that the combination of camrelizumab and sorafenib significantly improved the overall response rate and progression-free survival of patients with advanced HCC, but had no significant impact on overall survival. The combination therapy group exhibited more adverse events in terms of efficacy, but most of these adverse events were easily controlled after treatment. Further prospective randomized trials are needed to confirm the potential clinical benefits of this combination therapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Yongsheng Pang, Aydin Eresen, Zigeng Zhang, Qiaoming Hou, Yining Wang, Vahid Yaghmai, Zhuoli Zhang
Summary: Sorafenib is an approved oral medication for treating unresectable hepatocellular carcinoma. It targets growth factor receptors to reduce angiogenesis and inhibits cell proliferation. However, its effectiveness is limited and it can cause significant toxicities.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Shuhua Wei, Fenghua Wei, Mengyuan Li, Yuhan Yang, Jingwen Zhang, Chunxiao Li, Junjie Wang
Summary: Sorafenib, a multi-kinase inhibitor, has been approved for cancer treatment, especially hepatocellular carcinoma (HCC). However, many cancer patients acquire drug resistance to sorafenib in subsequent treatment, and the immunological mechanisms behind this resistance are still unclear. This review focuses on the immunoregulatory effects of sorafenib on the tumor microenvironment, the potential immunological mechanisms of therapeutic resistance, and the combination of sorafenib with immunotherapy to improve efficacy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Medicine, Research & Experimental
Sameh Saber, Alexandru Madalin Hasan, Osama A. Mohammed, Lobna A. Saleh, Abdullah A. Hashish, Mohannad Mohammad S. Alamri, Ahmed Y. Al-Ameer, Jaber Alfaifi, Ahmed Senbel, Adel Mohamed Aboregela, Tarig Babikir Algak Khalid, Mustafa Ahmed Abdel-Reheim, Simona Cavalu
Summary: Sorafenib is a first-line treatment for advanced hepatocellular carcinoma, but resistance mechanisms limit its long-term effectiveness. Our research shows that HSP90 plays a critical role in conferring resistance to sorafenib through inhibition of necroptosis and stabilization of HIF-1 alpha. By using ganetespib, an HSP90 inhibitor, we found that the combination therapy enhanced the effectiveness of sorafenib by activating necroptosis and destabilizing HIF-1 alpha. Additionally, LAMP2 aids in the degradation of MLKL, the mediator of necroptosis, through chaperone-mediated autophagy. These findings suggest that the combined therapy of ganetespib and sorafenib may offer a promising approach for the treatment of hepatocellular carcinoma.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Cell Biology
You-Liang Lai, Kai-Hung Wang, Hsing-Pang Hsieh, Wan-Ching Yen
Summary: DBPR114 showed activity against HCC tumor cell proliferation in vitro regardless of p53 alteration status and tumor grade. It induced growth inhibition in HCC cells through apoptosis induction, cell cycle arrest, and polyploidy formation. DBPR114 also exhibited anti-angiogenic effects and significantly inhibited tumor growth in multiple HCC tumor xenograft models.
JOURNAL OF BIOMEDICAL SCIENCE
(2022)
Article
Oncology
Chao Gao, Si-wei Wang, Jia-cheng Lu, Xiao-qiang Chai, Yuan-cheng Li, Peng-fei Zhang, Xiao-yong Huang, Jia-bin Cai, Yi-min Zheng, Xiao-jun Guo, Guo-ming Shi, Ai-wu Ke, Jia Fan
Summary: This study reveals the important role of KSR2 in the occurrence and development of HCC, and high expression of KSR2 is associated with poor prognosis. Mechanistically, the interaction between KSR2 and 14-3-3ζ plays a key role in the activation of the MAPK signaling pathway and drug resistance in HCC cells. Therefore, the KSR2-14-3-3ζ interaction may be a therapeutic target to enhance the sensitivity of HCC to sorafenib.
BIOMARKER RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Tadashi Kegasawa, Ryotaro Sakamori, Kazuki Maesaka, Ryoko Yamada, Yuki Tahata, Ayako Urabe, Takahiro Kodama, Hayato Hikita, Kazuho Imanaka, Kazuyoshi Ohkawa, Naoki Hiramatsu, Masahide Oshita, Yukinori Yamada, Masami Inada, Takayuki Yakushijin, Yasuharu Imai, Tomohide Tatsumi, Tetsuo Takehara
Summary: In patients with hepatocellular carcinoma, serum sodium levels are associated with the efficacy of sorafenib, with low sodium levels, high alpha-fetoprotein levels, and low AFP levels being independent prognostic factors for TTP.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Oncology
Giuseppa Augello, Maria Rita Emma, Antonina Azzolina, Roberto Puleio, Lucia Condorelli, Antonella Cusimano, Lydia Giannitrapani, James A. McCubrey, Juan Lucio Iovanna, Melchiorre Cervello
Summary: The study revealed that NUPR1 knock-down impaired autophagic flux, increasing cell sensitivity to sorafenib, and activated the p73 signaling pathway, enhancing the anti-tumor effects of the drug. Combined therapy with the p73 activator NSC59984 and sorafenib showed synergistic suppression of tumor growth, suggesting a novel approach for HCC treatment.
Article
Pharmacology & Pharmacy
Qiu-Chen Bi, Zhi-Qiang Deng, Yang-Feng Lv, Yue Liu, Chuan-Sheng Xie, Yuan-qiao He, Qun Tang
Summary: This study found that low Pi stress can enhance the sensitivity of hepatocellular carcinoma to sorafenib by suppressing the migration and invasion of cancer cells and inhibiting angiogenesis. Low Pi stress also decreased the viability of sorafenib-resistant cells by directly regulating the expression of specific proteins. In vivo analysis confirmed the enhanced sensitivity of hepatocellular carcinoma to sorafenib under low Pi stress. Overall, low Pi stress can improve the efficacy of sorafenib in treating hepatocellular carcinoma and expand the indications for sevelamer.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Mahmoud A. Younis, Ikramy A. Khalil, Yaser H. A. Elewa, Yasuhiro Kon, Hideyoshi Harashima
Summary: The usLNPs, composed of a novel pH-sensitive lipid, phospholipids, and a targeting peptide, demonstrated enhanced tumor accumulation, selectivity, and in vivo gene silencing. This combination therapy synergistically eradicated HCC in mice at a low dose of SOR and showed promising potential for clinical applications.
JOURNAL OF CONTROLLED RELEASE
(2021)
